- In April 2024, Medtronic plc, a global leader in medical technology, announced the expansion of its Evolut FX TAVR system for bicuspid aortic valve patients in select global markets, following successful clinical trials demonstrating improved valve placement accuracy and long-term outcomes. This development reflects Medtronic’s commitment to addressing the complex anatomical needs of BAVD patients through minimally invasive solutions, strengthening its position in the structural heart disease segment
- In March 2024, Edwards Lifesciences Corporation launched a post-market clinical study across Europe and North America evaluating the safety and performance of its SAPIEN 3 Ultra RESILIA valve in bicuspid aortic valve anatomies. The study aims to support expanded usage of transcatheter therapies in younger and lower-risk BAVD populations, emphasizing the company's innovation in durable and patient-tailored valve solutions
- In March 2024, Boston Scientific Corporation entered a strategic collaboration with academic medical centers in Asia-Pacific to research bicuspid valve disease prevalence and optimize regional intervention strategies. This initiative focuses on tailoring diagnostic and therapeutic approaches based on region-specific data, highlighting the growing need for localized clinical frameworks in congenital heart disease management
- In February 2024, Siemens Healthineers unveiled a next-generation cardiac MRI software module with AI-powered bicuspid valve analysis tools, aimed at enhancing diagnostic precision for structural heart diseases. The new technology enables faster, more accurate assessments of aortic valve morphology, streamlining care pathways and supporting early intervention for BAVD patients
- In January 2024, Abbott Laboratories launched a physician education initiative in collaboration with global cardiology societies to improve recognition and early diagnosis of bicuspid aortic valve disease in primary care. The program includes training modules on echocardiographic evaluation and risk stratification, underlining Abbott’s role in advancing cardiac diagnostics and patient outcomes through targeted clinician support
